Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SGMT 
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SGMT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.75
1 Year Target Price $25.75
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 141.82% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.85M USD | Price to earnings Ratio - | 1Y Target Price 25.75 |
Price to earnings Ratio - | 1Y Target Price 25.75 | ||
Volume (30-day avg) 7 | Beta 3.38 | 52 Weeks Range 1.73 - 11.41 | Updated Date 09/14/2025 |
52 Weeks Range 1.73 - 11.41 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.86 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.61% | Return on Equity (TTM) -37.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 94591008 | Price to Sales(TTM) 52.5 |
Enterprise Value 94591008 | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 31001100 | Shares Floating 22626577 |
Shares Outstanding 31001100 | Shares Floating 22626577 | ||
Percent Insiders 9.81 | Percent Institutions 29.21 |
Upturn AI SWOT
Sagimet Biosciences Inc. Series A Common Stock
Company Overview
History and Background
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of diseases with dysfunctional lipid metabolism. The company was founded in 2006 and went public in 2023.
Core Business Areas
- Drug Development: Focuses on developing and commercializing fatty acid synthase (FASN) inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and certain cancers.
Leadership and Structure
The company has a leadership team with expertise in drug development and commercialization. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments focused on research, clinical development, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Denifanstat (TVB-2640): Denifanstat is a FASN inhibitor being developed for NASH and certain cancers. It is currently in Phase 2b clinical trials for NASH. Market share is currently 0% as it is not yet approved. Key competitors include Madrigal Pharmaceuticals (resmetirom), Viking Therapeutics (VK2809), and Akero Therapeutics (efruxifermin).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and subject to regulatory changes. The NASH market is a large and growing market with significant unmet medical need.
Positioning
Sagimet is positioned as a company focused on developing novel therapeutics for NASH, leveraging its expertise in FASN inhibition.
Total Addressable Market (TAM)
The global NASH market is estimated to reach $50 billion by 2030. Sagimet is positioning itself to capture a significant share of this market with Denifanstat.
Upturn SWOT Analysis
Strengths
- Novel FASN inhibitor mechanism
- Clinical-stage asset with promising early data
- Experienced management team
- Strong intellectual property position
Weaknesses
- Single clinical-stage asset
- High cash burn rate
- Dependent on clinical trial success
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other indications
- NASH market growth
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other NASH therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Sagimet competes with other companies developing NASH therapies. Its competitive advantage lies in its novel FASN inhibitor mechanism. Currently, no revenue because no drugs have been approved yet.
Growth Trajectory and Initiatives
Historical Growth: Not applicable due to limited company history.
Future Projections: Future growth is dependent on the success of Denifanstat in clinical trials and its subsequent commercialization.
Recent Initiatives: Focus on advancing Denifanstat through clinical trials and preparing for potential commercialization.
Summary
Sagimet Biosciences is a clinical-stage biopharmaceutical company with a focus on developing novel therapeutics for NASH. The company's future depends heavily on the success of Denifanstat. The company will need to navigate regulatory hurdles and competition to be successful. Sagimet's experienced management team and novel FASN inhibitor mechanism give it a competitive edge. They will need to monitor cash burn and potential threats from larger firms and competitor's products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Investments in biopharmaceutical companies are inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.sagimet.com |
Full time employees 14 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.